NCT05621447View on ClinicalTrials.gov

A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

September 7, 2022

Primary Completion Date

November 3, 2022

Study Completion Date

February 22, 2023

Conditions

Healthy Male Subjects

Interventions

DRUG

TAS-303, [14C]TAS-303

oral administration on day 1

Trial Locations (1)

Unknown

A site selected by Taiho Pharmaceutical Co., Ltd., Tokyo

All Listed Sponsors

lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY